Bucher H C, Weinbacher M, Gyr K
Medizinische Universitäts-Poliklinik, Kantonsspital Basel, Switzerland.
BMJ. 1994 Sep 24;309(6957):761-4. doi: 10.1136/bmj.309.6957.761.
To determine whether the reporting of study results by using reductions in relative or absolute risk and the number needed to treat affects the views of physicians about the effectiveness of drugs to lower lipid concentrations and decisions about treatment.
Random allocation of two questionnaires presenting the results of three end points of the Helsinki heart study as results from separate trials by using reduction in either relative or absolute risk. In both questionnaires one end point was also presented by showing person years of treatment needed to prevent one myocardial infarction. The effectiveness of lipid lowering drugs was assessed for all end points on an 11 point scale. For each study result the likelihood to treat hypercholesterolaemia of 7.5 mmol/l in a healthy man had to be indicated on a seven point scale.
Random sample of 802 internists and general practitioners representative of providers of primary care in Switzerland.
The response rate was 69.6% (558). For the prevention of fatal and non-fatal myocardial infarction the mean ratings of effectiveness of lipid lowering drugs were 0.45 (95% confidence interval 0.21 to 0.69) and 1.39 (1.09 to 1.68) scale points lower when the reduction of absolute risk or number needed to treat were reported instead of the relative risk reduction (both P < 0.001). Physicians receiving trial results for identical end points in form of absolute reduction of risk or number needed to treat were less inclined to treat hypercholesterolaemia (both P < 0.001).
Physicians' views of the effectiveness of lipid lowering drugs and the decision to prescribe such drugs is affected by the predominant use of reduction of relative risk in trial reports and advertisements.
确定使用相对风险降低、绝对风险降低及需治疗人数来报告研究结果是否会影响医生对药物降低血脂浓度有效性的看法以及治疗决策。
随机分配两份问卷,以相对风险降低或绝对风险降低的形式将赫尔辛基心脏研究三个终点的结果呈现为独立试验的结果。在两份问卷中,还通过显示预防一例心肌梗死所需的治疗人年数来呈现一个终点。所有终点的降脂药物有效性均采用11分制进行评估。对于每项研究结果,必须在7分制上指出对一名健康男性治疗7.5 mmol/l高胆固醇血症的可能性。
从瑞士初级保健提供者中随机抽取802名内科医生和全科医生作为样本。
回复率为69.6%(558人)。对于预防致命和非致命性心肌梗死而言,当报告绝对风险降低或需治疗人数而非相对风险降低时,降脂药物有效性的平均评分分别低0.45分(95%置信区间0.21至0.69)和1.39分(1.09至1.68)(P均<0.001)。收到以绝对风险降低或需治疗人数形式呈现的相同终点试验结果的医生,治疗高胆固醇血症的意愿较低(P均<0.001)。
试验报告和广告中主要使用相对风险降低会影响医生对降脂药物有效性的看法以及开具此类药物的决策。